Sitagliptin mechanism of action
Pro Research Analysisby 
Searched over 200M research papers
Sitagliptin Mechanism of Action: DPP-4 Inhibition and Incretin Enhancement
Sitagliptin is primarily known as a selective inhibitor of the enzyme dipeptidyl peptidase-4 (DPP-4). By inhibiting DPP-4, sitagliptin prevents the breakdown of incretin hormones, such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). This leads to increased levels of these hormones, which in turn stimulate insulin secretion and suppress glucagon release, resulting in improved blood glucose control in patients with type 2 diabetes Makdissi2012Léger2024.
Anti-Inflammatory and Antioxidant Pathways
Modulation of Inflammatory Signaling
Sitagliptin has demonstrated significant anti-inflammatory effects across various tissues. It reduces the expression of pro-inflammatory cytokines such as interleukin-6 (IL-6), interleukin-1β (IL-1β), and tumor necrosis factor-alpha (TNF-α) in both vascular and neural tissues Kong2021Singh2024He2019+3 MORE. These effects are partly mediated by the suppression of DPP-4/CD26, which is involved in pro-inflammatory signaling Makdissi2012Léger2024. Sitagliptin also downregulates key inflammatory pathways, including nuclear factor-kappa B (NF-κB) and related kinases, further contributing to its anti-inflammatory action Makdissi2012Tang2016.
Activation of Antioxidant Pathways
Sitagliptin activates the p62–Keap1–Nrf2 signaling pathway, which enhances the cellular antioxidant response and reduces oxidative stress Kong2021Arab2021. This activation leads to increased nuclear translocation of Nrf2, promoting the expression of antioxidant enzymes and reducing reactive oxygen species (ROS) production Kong2021Arab2021. Additionally, sitagliptin stimulates the Nrf2/HO-1 pathway, further supporting its antioxidative properties .
Regulation of Cell Survival, Apoptosis, and Autophagy
AMPK, Akt, and mTOR Pathways
Sitagliptin modulates several key cell survival and metabolic pathways. It activates AMP-activated protein kinase (AMPK) and Akt, which are associated with enhanced cell survival and reduced apoptosis Al-Damry2018Arab2021Zeng2014+1 MORE. Sitagliptin also inhibits pro-apoptotic kinases such as glycogen synthase kinase-3β (GSK-3β) and p38 mitogen-activated protein kinase (p38MAPK), leading to decreased cell death in diabetic cardiomyopathy and other models Al-Damry2018Zeng2014. Furthermore, sitagliptin influences the AMPK/mTOR pathway, promoting autophagy and protecting against tissue injury .
SIRT6-Dependent and Other Protective Mechanisms
Sitagliptin upregulates SIRT6, a histone deacetylase involved in inflammation regulation, and this upregulation is essential for its anti-inflammatory effects in vascular tissues . The drug also suppresses the expression of endothelin-1 (ET-1) in the aorta by activating AMPK and inhibiting the NF-κB/IκBα system, contributing to vascular protection .
Neuroprotective and Anticancer Effects
Sitagliptin has shown neuroprotective effects by reducing oxidative stress, inflammation, and neuronal loss in models of drug-resistant epilepsy, partly through inhibition of protein kinase C-γ and modulation of long-term potentiation pathways . In cancer research, sitagliptin inhibits the metastatic potential of colorectal cancer cells by targeting DPP-4/CD26, reducing cell invasion and motility .
Conclusion
Sitagliptin’s mechanism of action extends beyond glucose regulation. By inhibiting DPP-4, it enhances incretin hormone activity, but it also exerts broad anti-inflammatory, antioxidant, anti-apoptotic, and tissue-protective effects through multiple signaling pathways, including AMPK, Akt, Nrf2, SIRT6, and mTOR. These multifaceted actions contribute to its therapeutic potential in diabetes, cardiovascular disease, neuroinflammation, and even cancer metastasis Kong2021Singh2024Al-Damry2018+7 MORE.
Sources and full results
Most relevant research papers on this topic